Modalis Therapeutics Corporation (Tokyo Mothers 4883) is developing precision genetic medicines through epigenetic gene modulation. Modalis is advancing therapies for orphan genetic diseases using its proprietary CRISPR-GNDM technology which enables the locus specific modulation of gene expression or histone modification without the need for double- stranded DNA cleavage, gene editing or base editing. Modalis is headquartered in Tokyo with laboratories and R&D facilities in Cambridge,
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $25M
Founded date: 2016
Investors 2
| Date | Name | Website |
| - | New Life S... | new-lifesc... |
| - | Medical In... | medicalinc... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.04.2019 | Series B | $25M | - |
Mentions in press and media 6
| Date | Title | Description |
| 05.11.2021 | Consolidated Financial Results for the Nine Months Ended September 30, 2021[Japanese GAAP] | Consolidated Financial Results for the Nine months ended September 30, 2021 [Japanese GAAP] November 5, 2021 Company name: Modalis Therapeutics Corporation Stock exchange listing: Tokyo Stock Exchange Code number: 4883 URL: https://www.moda... |
| 05.11.2021 | Notice Regarding the Recording of Non-Operating Income (Foreign Exchange Income) | This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no respons... |
| 05.08.2021 | Modalis Therapeutics : Notice regarding the recording of non-operating income (foreign exchange income) | This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no respons... |
| 06.05.2021 | MODALIS THERAPEUTICS CORPORATION Modalis Therapeutics : Notice regarding the recording of non-operating income (foreign exchange income) | This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no respons... |
| 29.03.2021 | MODALIS THERAPEUTICS CORPORATION Modalis Therapeutics : Additional Information Regarding the Infringement of the Lock-Up System by a Major Shareholder | This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no respons... |
| 29.03.2021 | Modalis Therapeutics : Additional Information Regarding the Infringement of the Lock-Up System by a Major Shareholder | This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no respons... |